Billionaire Profile
Yusuf Hamied
Global Rank
#1866

Image: India Post, Government of India | GODL-India | via Wikimedia Commons

Yusuf Hamied

CEO, Pharmaceuticals
INDIA
Real-Time Net Worth
$2.277B
Estimated based on Pharmaceuticals stock value as of April 21, 2026
-0.66% (24h)
Age
89
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
INDIA

Biography

Yusuf Khwaja Hamied, born in 1936, is an Indian scientist and billionaire businessman, most recognized as the non-executive chairman of Cipla, a leading pharmaceutical company. His career has been marked by his commitment to providing affordable healthcare, particularly in developing countries, by defying large pharmaceutical companies to offer generic drugs. With a net worth estimated at $2.5 billion as of 2024, he has received numerous awards, including the Padma Bhushan. Hamied's contributions extend beyond business, as he has supported education and healthcare initiatives.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/21/2026

Wealth Over Time

In-Depth Profile

Early Life

Yusuf Hamied was born on July 25, 1936, in Vilnius, Lithuania (then Poland). He was raised in Bombay (now Mumbai). His father, Khwaja Abdul Hamied, was an Indian Muslim, and his mother, Luba Derczanska, was a Russophone Lithuanian Jewish. He attended the Cathedral and John Connon School and St. Xavier's College in Mumbai before pursuing higher education in England.

Rise to Success

Hamied earned a BA in chemistry in 1957 and a PhD from Christ's College, Cambridge. He joined Cipla, founded by his father, and took over as chairman in 1989. His career is characterized by his efforts to make life-saving medications, especially for HIV/AIDS and other ailments, accessible to people in developing countries. He is known for providing affordable generic drugs, challenging the practices of large Western pharmaceutical companies. This earned him both recognition and controversy within the industry.

Key Business Strategies

Hamied pioneered the development of affordable, multi-drug combination pills for HIV/AIDS, tuberculosis, and asthma. His strategies involved expanding the production of bulk drugs and active pharmaceutical ingredients in India, thereby reducing costs and increasing access to medicine. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

Philanthropy

Hamied has been involved in several philanthropic initiatives. He has supported educational causes and contributed to healthcare facilities. He has made major donations to Cambridge University's chemistry department, including the foundation of the Hamied Scholars Programme. He also contributed to the IISER Pune for a state-of-the-art chemistry facility.

Career Milestones

1960

Joined Cipla

Joined the family business as a research officer after completing his PhD.

1976

Managing Director of Cipla

Became the Managing Director of Cipla.

1989

Chairman of Cipla

Became the Chairman of Cipla, continuing to lead the company's mission of providing affordable healthcare.

Philanthropy & Social Impact

Education

IISER Pune Chemistry Facility

$0.02B

Donated to IISER Pune for a state-of-the-art chemistry facility to be used in outreach programs.

Education

Hamied Scholars Programme

Unknown

Supported Cambridge University's chemistry department, leading to the foundation of the Hamied Scholars Programme.

Business Philosophy & Leadership

Notable Quotes

"Alleviation of suffering is my fundamental principle."

"I believe that life-saving, essential drugs should be freely available and the innovator should be paid a suitable royalty payment for his invention."

"I've done more humanitarian work than Gates and Buffett put together."

Leadership Principles

Affordable Healthcare

Prioritizing the availability of life-saving drugs at affordable prices for the masses.

Humanitarian Approach

Balancing business with a commitment to societal well-being and reducing suffering.

Innovation

Pioneering the development of multi-drug combination pills and pediatric formulations.

Controversies & Challenges

2012

Price Cuts for Cancer Drugs

Hamied caused controversy by slashing prices for cancer drugs, leading to legal challenges and debates.